News

Stay up to date on our
latest news and announcements.

News

Cytovation presents Phase I dose escalation results at ESMO

28/10/2022

Cytovation collaborates with Recurrent Respiratory Papillomatosis Foundation to expand its clinical investigations of CyPep-1 into rare neoplastic disease

08/02/2022

Cytovation raises $20 million in Series A financing round to advance clinical development of CyPep-1, a first-in-class targeted tumor membrane immunotherapy

26/01/2022

CyPep-1 Shows Preliminary Safety, Tolerability and Early Signs of Efficacy in Part 1 of its Ph I/IIa CICILIA Trial Which Now Moves to Expansion Phase

25/09/2021

Cytovation Announces Clinical Collaboration with MSD to Evaluate its First-in-class Tumorolytic Agent CyPep-1 in Combination with KEYTRUDA

30/06/2021

Cytovation Announces Dosing of First Patient in its Phase I/II CICILIA Trial Investigating CyPep-1 in Patients with Solid Cancers

29/05/2020

Cytovation and SMS-oncology sign agreement on conduct of phase I/II trial with CyPep-1 in solid tumors

08/08/2019

Cytovation initiates clinical development programme with CyPep-1,a first-in-class lytic agent for tumor immunotherapy

18/03/2019

Cytovation announces appointment of Ole-Erik Iversen as Scientific Advisor

20/01/2017

Cytovation announces two key appointments to the management team

03/10/2016

© 2022 Cytovation ASA | All Rights Reserved
Webdesign by Limedrop

Terms & Conditions | Privacy & Cookies | Code of Ethics

© 2022 Cytovation ASA | All Rights Reserved | Webdesign by Limedrop
Terms & Conditions | Privacy & Cookies | Code of Ethics